Scholarlink

Purpose <p>The purpose of this study was to identify genetic mutations in patients with localized and metastatic prostate cancer, exploring the relationship between these mutations and clinical outcomes.</p> Materials and methods <p>We conducted next-generation sequencing on tissue samples from 106 prostate cancer patients at Seoul St. Mary’s Hospital, analyzing prostate-specific antigen (PSA) levels, tumor, node, metastasis (TNM) staging, Gleason score (GS), and clinical course, including treatment modalities and biochemical recurrence (BCR).</p> Results <p>The study included 65 patients with localized and 41 with metastatic prostate cancer. Significant differences were noted in PSA levels, T stage, GS, and treatment modalities. We observed prevalent single-nucleotide variations (SNVs), copy number variations (CNVs), and structural variations including gene fusions like TMPRSS2-ERG. Key predictors of metastatic prostate cancer identified were T stage, GS, PIK3CA, LRP6, LRRK2, and APOBEC3B deletion. BRCA2, BCL6, and CHEK2 were significant predictors for BCR.</p> Conclusion <p>Our findings suggest that specific genetic mutations, including PIK3CA, LRP6, LRRK2, and BRCA2, are linked to prostate cancer metastasis and BCR. These results highlight the potential of genetic analysis in forecasting the prognosis of prostate cancer patients and guiding therapeutic decisions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic alterations of prostate cancer: in localized and metastatic prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月14日

查看全文
  • Chang Eil Yoon,
  • San Kang,
  • Seung ah Rhew,
  • Hyeok Jae Kwon,
  • Dongho Shin,
  • Hyong Woo Moon,
  • Mee Young Kim,
  • Ji Youl Lee

摘要

Purpose

The purpose of this study was to identify genetic mutations in patients with localized and metastatic prostate cancer, exploring the relationship between these mutations and clinical outcomes.

Materials and methods

We conducted next-generation sequencing on tissue samples from 106 prostate cancer patients at Seoul St. Mary’s Hospital, analyzing prostate-specific antigen (PSA) levels, tumor, node, metastasis (TNM) staging, Gleason score (GS), and clinical course, including treatment modalities and biochemical recurrence (BCR).

Results

The study included 65 patients with localized and 41 with metastatic prostate cancer. Significant differences were noted in PSA levels, T stage, GS, and treatment modalities. We observed prevalent single-nucleotide variations (SNVs), copy number variations (CNVs), and structural variations including gene fusions like TMPRSS2-ERG. Key predictors of metastatic prostate cancer identified were T stage, GS, PIK3CA, LRP6, LRRK2, and APOBEC3B deletion. BRCA2, BCL6, and CHEK2 were significant predictors for BCR.

Conclusion

Our findings suggest that specific genetic mutations, including PIK3CA, LRP6, LRRK2, and BRCA2, are linked to prostate cancer metastasis and BCR. These results highlight the potential of genetic analysis in forecasting the prognosis of prostate cancer patients and guiding therapeutic decisions.